Download Streptococcus pneumoniae (neumococo)

Capítulo 175 Streptococcus pneumoniae (neumococo) & e175-1
© ELSEVIER. Fotocopiar sin autorización es un delito.
BIBLIOGRAFÍA
American Academy of Pediatrics: Recommendations for the prevention of
Streptococcus pneumoniae infections in infants and children: use of
13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23), Pediatrics 126:186-190, 2010.
American Academy of Pediatrics: Red book: 2009 report of the Committee on Infectious Diseases, ed 28, Elk Grove Village, IL. pp.
524–535.
Centers for Disease Control and Prevention: Licensure of 1 13-valent
pneumococcal conjugate vaccine (PCV13) and recommendations
for use among children—ACIP, 2010, MMWR Morb Mortal
Wkly Rep 59:258-261, 2010.
Centers for Disease Control and Prevention: Effects of new penicillin
susceptibility breakpoints for Streptococcus pneumoniae—United
States, 2006-2007, MMWR Morb Mortal Wkly Rep 57:1353-1357,
2008.
Centers for Disease Control and Prevention: Direct and indirect effects of
routine vaccination of children with 7-valent pneumococcal conjugate
vaccine on incidence of invasive pneumococcal disease—United
States, 1998-2003, MMWR Morb Mortal Wkly Rep 54:893-897,
2005.
Centers for Disease Control and Prevention: Emergence of antimicrobialresistant serotype 19A Streptococcus pneumonia—Massachusetts,
2001-2006, MMWR Morb Mortal Wkly Rep 56:1077-1080, 2007.
Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before
and after the introduction of the pneumococcal conjugate vaccine,
Clin Infect Dis 44:1428-1433, 2007.
Hendrickson DJ, Blumberg DA, Joad JP, et al. Five-fold increase in
pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine, Pediatr Infect Dis J 27:1030-1032, 2008.
Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate
vaccine on pneumococcal meningitis, N Engl J Med 360:244-256,
2009.
Huss A, Scott P, Stuck AE, et al. Efficacy of pneumococcal vaccination
in adults: a meta-analysis, CMAJ 180:48-58, 2009.
Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common
serotype causing invasive pneumococcal infections in children,
Pediatrics 125:429-436, 2010.
Kaplan SL, Mason EO, Barson WJ, et al. Outcome of invasive infections
outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriaxone in children treated
with beta-lactam antibiotics, Pediatr Infect Dis J 20:392-396, 2001.
Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the
pneumococcal conjugate vaccine on drug-resistant Streptococcus
pneumonia, N Engl J Med 354:1455-1463, 2006.
Lucero MG, Nohynek H, Williams G, et al. Efficacy of an 11-valent
pneumococcal conjugate vaccine against radiologically confirmed
pneumonia among children less than 2 years of age in the
Philippines, Pediatr Infect Dis J 28:455-462, 2009.
Lynch JP, Zhanel GG: Streptococcus pneumonia: does antimicrobial
resistance matter? Semin Respir Crit Care Med 30:210-238, 2009.
Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial
pneumonia as a cause of death in pandemic influenza: implications for
pandemic influenza preparedness, J Infect Dis 198:962-970, 2008.
Musher DM, Rueda-Jaimes AM, Graviss EA, et al. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients
with bacteremic and nonbacteremic pneumococcal pneumonia, Clin
Infect Dis 43:1004-1008, 2006.
Neuman MI, Harper MB: Time to positivity of blood cultures for
children with Streptococcus pneumoniae bacteremia, Clin Infect
Dis 33:1324-1328, 2001.
O’Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by
Streptococcus pneumoniae in children younger than 5 years: global
estimates, Lancet 374:893-902, 2009.
Ongkasuwan J, Valdez TA, Hulten KG, et al. Pneumococcal mastoiditis
in children and the emergence of multidrug-resistant serotype 19A
isolates, Pediatrics 122:34-39, 2008.
Park SY, Van Beneden CA, Pilishvili T, et al. invasive pneumococcal
infections among vaccinated children in the United States, J Pediatr
156:478-483, 2010.
Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent
and multidrug resistant pneumococcus in Massachusetts following
universal immunization of infants with pneumococcal conjugate
vaccine, Pediatr Infect Dis J 26:468-472, 2007.
Pichichero ME, Casey JR: Emergence of a multiresistant serotype 19A
pneumococcal strain not included in the 7-valent conjugate vaccine
as an otopathogen in children, JAMA 298:1772-1778, 2007.
Poehling KA, Lafleur BJ, Szilagyi PS, et al. Population-based impact of
pneumococcal conjugate vaccine in young children, Pediatrics
114:755-761, 2004.
Reefhuis J, Honein MA, Whitney CG, et al. Risk of bacterial meningitis
in children with cochlear implants, N Eng J Med 349:335-345,
2003.
Reinert P, Benkerrou M, Montalembert M, et al. Immunogenicity and
safety of a pneumococcal conjugate 7-valent vaccine in infants with
sickle cell disease, Pediatr Infect Dis J 26:1105-1109, 2007.
Rello J, Lisbon T, Lujan M, et al. Severity of pneumococcal pneumonia
associated with genomic bacterial load, Chest 136:832-840, 2009.
Talbot TR, Poehling KA, Hartert T, et al. Reduction in high rates of
antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine, Clin
Infect Dis 39:641-651, 2004.
Von Gottberg A, Klugman KP, Cohen C, et al. Emergence of levofloxacinnon-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study, Lancet 371:1108-1113, 2008.
Waters AM, Kerecuk L, Luk D, et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience, J Pediatr 151:140-144, 2007.